Pelthos Therapeutics Inc. Common Stock (NY:PTHS)

16.54 +0.80 (+5.08%)

Official Closing Price Updated: 4:10 PM EDT, Oct 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pelthos Therapeutics Inc. Common Stock

Pelthos (PTHS) Q2 2026 Earnings Call Transcript ↗

August 20, 2026

ZELSUVMI revenue jumped 45% as prescriber count surged and new PBM contracts drove adoption.

Via The Motley Fool

Topics Earnings

Pelthos Therapeutics Q2 Earnings Call Highlights ↗

August 14, 2026

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported second-quarter revenue growth as prescriptions for its lead product, ZELSUVMI, increased following the treatment’s July 2025 commercial launch. The...

Via MarketBeat

Topics Earnings

Pelthos Therapeutics Q1 Earnings Call Highlights ↗

May 15, 2026

Pelthos Therapeutics (NYSEAMERICAN:PTHS) reported higher first-quarter revenue as prescriptions for its lead product, ZELSUVMI, continued to grow in the treatment’s third full quarter since launch,...

Via MarketBeat

Topics Earnings

Pelthos Therapeutics Inc (NYSEARCA:PTHS) Revenue Beats Estimates in Q1 2026, Net Loss Narrows ↗

May 14, 2026

Via Chartmill

Pelthos Therapeutics Inc. (PTHS) Reports Strong Q4 2025 Earnings Beat Amid Muted Market Reaction ↗

March 19, 2026

Via Chartmill

Topics Earnings

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

Pelthos Therapeutics Inc (NYSEARCA:PTHS) Stock Rises on Strong Q3 Revenue Beat ↗

November 13, 2025

Pelthos Therapeutics (PTHS) Q3 2025 results show a huge 66% revenue beat driven by strong demand for its new product ZELSUVMI, despite a significant EPS loss.

Via Chartmill

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch ↗

November 07, 2025

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 03, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 11, 2025

Via Benzinga

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts ↗

July 10, 2025

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Via Stocktwits

Topics Government

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

July 10, 2025

Via Benzinga

Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease ↗

July 10, 2025

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 09, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 08, 2025

Via Benzinga

Helius Medical Technologies, Sunrun And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 08, 2025

Via Benzinga

Why ENDRA Life Sciences Shares Are Trading Higher By Over 61%; Here Are 20 Stocks Moving Premarket ↗

July 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 07, 2025

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.